
Arbor Biotechnologies is a biotechnology company focused on developing programmable DNA editors to create bespoke genetic medicines. Their innovative approach aims to shift the paradigm from treatment to functional cures for genetic diseases. With a proprietary portfolio of DNA editors capable of addressing over 90% of the human genome, Arbor is positioned to unlock therapeutic opportunities across a wide range of diseases. The company has attracted significant investment and has established partnerships to advance its gene editing technologies, making it a key player in the genetic medicine landscape.

Arbor Biotechnologies is a biotechnology company focused on developing programmable DNA editors to create bespoke genetic medicines. Their innovative approach aims to shift the paradigm from treatment to functional cures for genetic diseases. With a proprietary portfolio of DNA editors capable of addressing over 90% of the human genome, Arbor is positioned to unlock therapeutic opportunities across a wide range of diseases. The company has attracted significant investment and has established partnerships to advance its gene editing technologies, making it a key player in the genetic medicine landscape.
Who are we? Arbor Biotechnologies™, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company’s unique suite of optimized gene editors goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbor’s lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, progressing into clinical trials, the company continues to focus their research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures. For more information, please visit: arbor.bio.
Who are you? Passionate, determined, and accountable. Curious, resourceful, innovative, forward thinking, and resilient. Authentic, humble, open-minded and puts team above self. At Arbor, our people embrace these qualities, so if this sounds like you then please read on!
About The Role The Medical Director, Clinical Development will provide medical, scientific, and operational leadership for clinical programs in rare and neurological diseases, with particular focus on early-stage and proof-of-concept studies for gene-editing therapeutics. Reporting to the Chief Medical Officer, this individual will serve as a senior clinical leader responsible for driving the design, execution, and optimization of clinical studies across global regions. A critical component of the role includes establishing and overseeing investigator-initiated trials (IITs) in China, requiring strong communication skills and the ability to travel to China to build and maintain key academic and operational partnerships.
This role is ideal for a physician-scientist who thrives in a fast-moving biotech environment, is hands-on with clinical execution, and combines scientific rigor with operational excellence.
What You Can Expect Clinical Strategy & Program Execution
China IIT Development & Operational Leadership
Global Clinical Development & Regulatory Support
Cross-Functional & Matrix Collaboration
External Engagement & Scientific Leadership
What You Bring
Our Values Our values govern the work we do at Arbor, and we’re hoping that they resonate as strongly with you as they do with us!
The anticipated salary range for candidates for this role will be $225,000 - $305,000. The final salary offered will depend on several factors, which may include, but is not limited to relevant years of experience, educational background, industry knowledge, technical skills, and other factors that may prove relevant during the interview process.
We promote diversity and inclusion not just in our recruitment processes, but in everything we do. We’re an equal opportunity employer and we will continue to ensure our recruitment process is free of bias and our workplace is inclusive, positive, and free of discrimination and respecting of all backgrounds and beliefs.